COVID And Medicare: Pricing Restraints Needed For Part B Vaccines, MedPAC Panelists Say

GSK’s blockbuster Shingrix and other Part D vaccines would be switched to Part B under proposal being developed by influential advisory commission. Lack of pricing controls in Part B is generating concerns among panelists, though, as MedPAC aims to finalize its recommendations on revising Medicare reimbursement for vaccines by next spring.

Medical concept Vaccination vaccine vial dose flu shot drug needle syringe,Lab test research science hypodermic injection treatment disease care hospital prevention immunization illness disease baby.
Vaccine Costs Have MedPAC's Attention

The Medicare Payment Advisory Commission may suggest new tools enhancing Medicare’s ability to control pricing for Part B vaccines, including future COVID-19 vaccines, in upcoming recommendations to change the program's approach to coverage in order to expand access.

Consolidating reimbursement of all vaccines under Part B and eliminating cost sharing was the option that generated the strongest support...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet